Background: Treatment of patients with locally advanced rectal cancer (LARC) is based on a combination of chemo-radiotherapy (CRT) and surgery. The rate of distant recurrences remains over 25%. Circulating cell-free DNA (cfDNA) in plasma is a mixture of normal and cancer-specific DNA segments and is a promising biomarker in patients with colorectal cancer. The aim of our study was to investigate plasma cfDNA as a prognostic marker for outcome in patients with LARC treated with neoadjuvant CRT and surgery.
Introduction
Rectal cancer is a frequent and deadly malignant disease, with 400 000 new cases predicted to occur every year worldwide [1] . Locally advanced rectal cancer (LARC) remains a challenging disease requiring a multidisciplinary approach, combining surgery with radiotherapy and chemotherapy for optimal outcome. Preoperative chemo-radiotherapy (CRT) before surgery is considered the standard of care for patients with LARC, reducing the risk of pelvic recurrence but with limited impact on survival [2, 3] . In appropriately selected patients with high risk LARC, induction chemotherapy (ICT) before CRT has been proposed as an option for better long-term outcome [4] [5] [6] [7] . The theoretical benefit of this neoadjuvant approach is early treatment of micrometastases, potentially reducing the risk of distant failures and improving survival, although this approach remains to be tested in a randomized setting. Despite neoadjuvant treatment with CRT and ICT, the rate of distant recurrences from LARC of around 25% is still discouragingly high. New prognostic biomarkers are needed to improve the selection of patients for CRT and ICT to ensure appropriate therapy and follow-up.
Circulating nucleic acids in the bloodstream were first recognized by Mandel in 1948 [8] , with further emphasis on their presence in cancer patients by Leon in 1977 [9] . Cell-free DNA (cfDNA) constitutes a mixture of normal DNA fragments and cancer-specific DNA segments with tumor-specific mutations. This has led to the concept of liquid biopsies involving the application of cfDNA measured as either total concentrations of cfDNA or tumor-specific alterations, and this concept has attracted increasing interest in many forms of cancer including colorectal cancer (CRC) [10, 11] .
Total cfDNA level is measurable in the bloodstream in both malignant and non-malignant diseases, with a higher concentration in patients with CRC compared with patients with various medical diseases [10, 12] . CfDNA can be quantified with various techniques including quantitative polymerase chain reaction (qPCR), droplet digital PCR, BEAMing, and NGS, all of which involve a relatively high level of effort, laboratory requirements, and costs [11] . A new simplified technique of cfDNA quantification based on a direct fluorescent assay has shown promising results [13, 14] .
The aim of this study was to investigate the plasma level of cfDNA measured by a fluorescent assay as a prognostic marker for patients with LARC treated with neoadjuvant CRT and surgery.
Methods

Patients
From 2009 to 2014, 123 patients with LARC were included in two biomarker studies, BIOREC and RECCET, at the Department of Oncology, Herlev & Gentofte University Hospital, Denmark. Inclusion criteria were histopathologically verified adenocarcinoma in the rectum, localized <15 cm from the anal verge by rigid proctoscopy. LARC was defined as tumors invading surrounding structures or the peritoneum (all T4 tumors), T3 tumors extending to within 1 mm of or beyond the mesorectal fascia (i.e. CRM threatened or involved), or T3-4 Nþ tumors as defined by magnetic resonance imaging (MRI). Pretreatment evaluation included a pelvic MRI scan and a computed tomography (CT) scan of the chest and abdomen, assessed by a multidisciplinary team of gastrointestinal surgeons, oncologists, radiologists, and pathologists.
Treatment
All patients were treated with long-course CRT comprising concomitant capecitabine (650 mg/m 2 b.i.d. on treatment days) with or without oxaliplatin (50 mg/m 2 weekly), according to local guidelines. Radiotherapy was delivered as fixed field IMRT or VMAT 54 Gy in 27 fractions to the tumor bed and 48.6 Gy in 27 fractions to the regional lymph nodes and extending to the promontory. In addition, all patients from the RECCET study and 20 patients from the BIOREC study received one to three cycles of ICT chemotherapy with capecitabine (650 mg/m 2 b.i.d.) and oxaliplatin (85 mg/m 2 ). TME surgery was scheduled 6-8 weeks after CRT.
Plasma samples and cfDNA measurements
Plasma samples were collected prospectively at baseline, after the ICT, and after CRT. For the patients included in the RECCET study, a serial collection of plasma samples was conducted during a 5-year follow-up after surgery, along with CT scans every 3 months for the first year, every 6 months for the next 2 years, and every 12 months for the last 2 years.
Plasma was obtained from blood samples collected in citrate tubes and centrifuged at 2000 g for 10 min at 4 C within 2 h of collection, then stored at À80 C.cfDNA levels were detected according to a modified version of the method described by Douvdevani et al. [15] . Forty microliters of plasma was added to 160 ll PBS containing DMSO (1 : 8) and SYBR V R Gold Nucleic Acid Gel Stain (1 : 8000) (Invitrogen). Fluorescence was measured with a 96-well fluorometer (Infinite F200 PRO, Tecan) at an emission wavelength of 535 nm and an excitation wavelength of 485 nm in a black 96-well plate (Bio-Plex Pro Flat Bottom Plates, Bio-Rad).
DNA standards were prepared from Human Control Genomic DNA (Life Technologies) diluted 1 : 5 in PBS containing 10% bovine serum albumin (BSA; Sigma V R Life Science). The concentrations of the samples were calculated from a standard curve. The goodness-of-fit of all standard curves (R 2 ) was above 0.97.
The final concentration of each sample was calculated as the mean of four measurements. Outliers were removed according to Dixons q test if the standard deviation exceeded 10% (12 outliers were removed in the entire dataset).
Ethics
The RECCET and BIOREC studies were approved by the Regional Ethics 
Statistical analysis
The correlations between patient characteristics, IUCC stage, and cfDNA were investigated by non-parametric Mann-Whitney test or Fischer's exact test when appropriate. Survival analyses were evaluated by KaplanMeier (KM) plots, and any differences between the groups were estimated by the log-rank method.
Hazard ratios (HRs) were estimated with a Cox proportional hazards regression model. A multivariable Cox regression analysis was carried out to examine whether the different variables were associated with disease recurrences and overall survival (OS). Time to recurrence was calculated from the date of treatment start until local or distant recurrence. Disease-free survival (DFS) was calculated from the date of treatment start until local recurrence, distant recurrence, or death from any cause. OS was calculated from date of treatment start until death of any cause or censored at last follow-up.
Results
Patients
A total of 123 patients were included in our biomarker study. All patients commenced preoperative treatment with CRT and 117 proceeded to surgery. Seventy-one (58%) of the patients also received ICT before CRT. Patient flow is illustrated in a consort diagram (supplementary Figure S1 , available at Annals of Oncology online), and baseline characteristics presented in Table  1 . The median follow-up time was 55 months for recurrence and OS. Eight (6.5%) and 34 (27.6%) patients experienced local and distant recurrence, respectively. Four patients with local recurrence experienced distant recurrence during follow-up. Thirty-nine patients (31.7%) died. The results of the clinical study have been published separately [6] .
Baseline plasma cfDNA levels and correlation to patients' characteristics
The mean and median baseline cfDNA levels were 1.05 and 0.94 ng/mL, respectively. No significant differences were observed between baseline levels and levels after treatment. The median baseline levels of cfDNA were analyzed in relation to baseline characteristics, and data showed a difference in gender distribution but no significant differences according to age, stage, T-classification, N-positivity, or location of the primary tumor. Similarly, there was no significant difference in baseline cfDNA levels between patients who achieved a complete pathological response (pCR) and the poor responders. The same applied when the samples drawn before surgery were analyzed.
Prognostic value of plasma cfDNA
When grouped into quartiles of baseline plasma cfDNA, an association between cfDNA levels and outcome was found in favor of patients with the lowest levels (supplementary Figure S2 , available at Annals of Oncology online). Patients with baseline cfDNA levels above the 75th quartile had a higher risk of local or distant recurrence and shorter time to recurrence compared with patients with plasma cfDNA below (HR ¼ 2.48, 95% CI: 1.3-4.8, P ¼ 0.007). The same applied to DFS (HR ¼ 2.43, 95% CI: 1.27-4.70, P ¼ 0.015). Kaplan-Meier curves for time to recurrence and DFS are shown in Figure 1A and B. A similar tendency was observed for OS, but not statistically significant. The baseline plasma level of cfDNA remained a significant prognostic biomarker in a Cox regression multivariate analysis including cfDNA levels, age, gender, complete pathological response (pCR), positive lymph nodes (ypNþ), distance to mesorectal fascia (MRF), and free resection margin (R0 resection; Table 2 ). Supplementary Figures S3-S6 , available at Annals of Oncology online show KM plots for 25th and 50th quartile cut-off and supplementary Table S1 , available at Annals of Oncology online with multivariate analyses with level of cfDNA as a continuous variable and in quartiles.
Seventy-one (58%) of the patients received one to three cycles of ICT with capecitabine and oxaliplatin. The prognostic impact of plasma levels of cfDNA in this subgroup of patients remained significant for time to recurrence and DFS (Figure 1C and D; Table 2 ). cfDNA measured after ICT and before start of CRT, showed that high cfDNA was prognostic for DFS (HR ¼ 2.68, 95% CI: 1.21-5.94, P ¼ 0.015).
Serial samples were obtained from 51 (41%) patients included in the RECCET protocol.
The prognostic value of cfDNA plasma levels remained significant in sample collected one year after surgery and in the last available time-point. HRs for high cfDNA measured from the last available sample during follow-up were 2.54 (95% CI: 1.1-5.82, P ¼ 0.028) and 2.67 (95% CI: 1.07-6.65, P ¼ 0.03) for DFS and OS, respectively. Kaplan-Meier curves are shown in Figure 2A and B.
Discussion
Treatment of patients with LARC comprises of chemotherapy, radiotherapy, and surgery, with a consistent challenge in terms of patient selection. A reduction in the risk of local failures has not translated into a survival benefit due to a high risk of distant metastases. Today, staging and treatment selection of patients with LARC are based mainly on imaging, with its known limitations, and in some countries on the carcinoembryonic antigen (CEA) measurement [16] . Our results indicate that high plasma cfDNA levels are associated with the development of local and distant recurrences, i.e. treatment failure in patients with LARC. This association was sustained after adjusting for other prognostic factors in the multivariate analysis. Since serum CEA is not routinely used in our country, CEA was not included, but a review of CEA and cfDNA has demonstrated some correlation, but with superior clinical value of the cfDNA measurement [17] .
We measured cfDNA levels before, during, and after treatment with ICT, CRT, and surgery. Additionally, follow-up plasma samples were obtained from 51 (41%) of the patients. The observed association between high plasma levels of cfDNA and risk of treatment failure was consistent over time, which may help determine distant treatment failure at an earlier time point and hereby identify patients with oligometastatic disease who are still candidates for curative treatment.
Since patients with LARC hold a small tumor load (compared with mCRC) a large proportion of the patients are expected to have cfDNA levels close to healthy individuals. Consequently, a direct correlation to outcome based on a continuous measure on the lower ranges is not to be expected. From the analysis on cfDNA levels in quartiles, a relevant cut-off in this cohort was defined by the 75% upper quartile. In multivariate analysis designed to include cfDNA in quartiles, as continuous parameter, and lower cut points, the significant tendency was sustained, although not as pronounced as when testing the dichotomized 75% quartile, underlining our biological theories. An external UNL and comparison between cohorts and has yet to be defined since this is the first study in this setting and with this method. Handling cfDNA as a continuous variable does not reach statistical significance based on the P-values although inspection of the point estimate for the HRs and the corresponding span of the 95% CIs (0.84-8.39 and 0.79-5.46) clearly indicate a potential clinical impact of baseline cfDNA also as a continuous variable.
Most published studies have investigated the tumor specific DNA (ctDNA), and not the total cfDNA. Only a few studies have investigated the association between the response of preoperative CRT and cfDNA in patients with rectal cancer, indicating a difference in biological behavior regarding responders versus nonresponders [18] [19] [20] [21] . CtDNA level was correlated to resection status and tumor burden in patients with CRC in a study from 2008 [22] and a recent study demonstrated that post-operative detection of ctDNA has a major potential in predicting recurrence after localized CRC [23] . Whereas these studies undoubtedly will bring new tools for individualized therapy in rectal cancer patients, the NPV and PPV of these tests are yet to be described, a major task due to the low frequency of positive postoperative samples and extensive laboratory workload needed to fit an individualized ctDNA detection. Our current simple method supplements these data in terms of a pre-treatment basic prognostic assessment of the full patient's cohort, taking into account not only the tumor specific DNA, but the full biological picture of the combined measure of cfDNA in the plasma.
In our study, we quantified the level of total cfDNA by a rapid direct fluorescent assay introduced by Douvdevani et al. [15] , taking into considerations that the measure is not absolutely cancer specific, it is influenced by comorbidity [24] , and cannot be adjusted for contamination by normal lymphocytes, as described in relation to PCR-based techniques [25] . However, in contrast to the traditional PCR-based techniques, this method is advantageous because laboratory feasibility is increased. Our approach needs further investigations, including definition of an upper normal limit for future studies.
We propose that quantification of plasma levels of cfDNA could provide clinicians with a new tool for an improved handling of patients with LARC, supporting the data in mCRC [26] , as prognostic marker contributing to accurate staging and selection of treatment strategy.
The development toward a more simplified laboratory approach can facilitate the integration of cfDNA into daily practice. This gives an opportunity for selecting patients at risk for distant recurrence for more intensified treatment and for preventing unnecessary treatment in low risk patients. In conclusion, we report a relation between a high baseline plasma level of total cfDNA and increased risk of distant recurrence, shorter time to recurrence, and short DFS in patients with LARC treated with neoadjuvant CRT, consistent at any time point during the follow-up period after surgery. Consequently, cfDNA measured by this rapid and less expensive assay could contribute to individualized therapy in patients with LARC.
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